Skip to main navigation Skip to search Skip to main content

Galectin-3: A new biomarker for heart failure progression and prognosis

  • University Medical Centre Groningen

Research output: Contribution to journalReview articleAcademicpeer-review

1 Citation (Scopus)

Abstract

Galectin-3 is a carbohydrate-binding protein involved in inflammatory and fibrotic processes in various tissues. In the heart, galectin-3 activation has been associated with progression of cardiac fibrosis leading to cardiac remodeling and heart failure development. Clinical studies have shown that galectin-3 is a valuable prognostic marker in cardiovascular disease recognizing patients at risk. Most published results are from cohorts with chronic heart failure patients, but also in patients with acute heart failure, acute cardiac syndromes, as well as in cohorts from the general population. Galectin-3 levels were prognostic when looking at various endpoints, most prominently mortality, new onset heart failure and other cardiovascular endpoints. This review on galectin-3 provides an overview of the biological function of the marker and important findings from animal model studies and summarizes the key results of published analyses of clinical cohorts. The potential future role of galectin-3 is discussed.

Original languageEnglish
Pages (from-to)251-260
Number of pages10
JournalLaboratoriumsMedizin
Volume37
Issue number5
DOIs
Publication statusPublished - Sept 2013
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Galectin-3: A new biomarker for heart failure progression and prognosis'. Together they form a unique fingerprint.

Cite this